Defect of Articular CartilagePhase 4NCT02539030
Comparison of Efficacy and Safety of Microfracture and Modified Microfracture
A Phase 4 study testing Microfracture and CartiFill in people with Defect of Articular Cartilage and Osteoarthritis, run by Cellontech Co., Ltd. at 12 sites in South Korea.
Trial summary
This study was designed to evaluate the efficacy and safety of a modified microfracture using collagen, and to compare them with those of a simple microfracture to prove the non-inferiority of the modified microfracture using collagen in patients with cartilage defects in their knees. Read more about this study
- Who is it for?
- Ages 15 years and olderHealthy volunteers can take part
- Conditions the study is for
- Defect of Articular Cartilage, Osteoarthritis, Traumatic Arthritis
- What is being tested?
- Microfracture and CartiFill
- Type of treatment
- Medical device, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 12 sitesSouth Korea
- Study dates
- Feb 2013to Jun 2017
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 15 years and older
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- 1. Patients with cartilage defects in their knee (Including Knee OA and Knee TA) 2. Knee osteoarthritis patients whose Kellgren-Lawrence Grading Scale score is lower than 3 (patients who received simultaneous or previous correction will be excluded).
- 3. Patients with misalignment of their tibia and femur, unstable ligament in their knee, or bony defects in the lesions of their knee, and/or who had been treated for alignment 4. Patients who were 15 years old or older 5. Patients or their representative (for adults), or patients and their parent/guardian (for minors), who agreed to participate in the study and signed the informed consent form
Who cannot join
- 1. If patients or their families suffer from or have ever suffered from an autoimmune disease.
- 2. Patients who have ever suffered an anaphylactic reaction. 3. Patients who have ever suffered hypersensitivity to an implant. 4. Patients with a history of allergy to porcine or bovine protein. 5. Subjects with inflammatory arthritis, such as rheumatoid and gouty arthritis.
- 6. Subjects with autoimmune disease related arthritis. 7. Subjects who are pregnant and/or breast-feeding and/or plan a pregnancy. 8. Subjects with tumors. 9. Subjects who have undergone radiotherapy or chemotherapy within the last 2 years (Exception: if the possibility of collagen treatment is confirmed with doctor's clinical decision).
- 10. Subjects who are diabetic. (Exception: if the possibility of CartiFill™ treatment is confirmed with doctor's clinical decision, and/or patient's blood glucose level remains within the normal range and/or no other complications by diabetes mellitus.) 11. Subjects with infections, currently on treatment with antibiotics or antimicrobials (Exception: if the possibility of collagen treatment is confirmed with doctor's clinical decision).
- 12. Subjects under adrenocorticoid therapy (Exception: if the possibility of collagen treatment is confirmed with doctor's clinical decision).
- 13. Subjects with psychiatric disorders who are considered inappropriate to participate in this trial by the Principal Investigator.
- 14. Patients who have ever suffered contraindications of the used Fibrin sealant. (The major contraindications are as follows: patients with hypersensitivity to aprotinin and those treatments for severe brisk arterial or venous bleeding.)
Trial locations and contacts
12 sites in 1 country.
12 sites in 1 country
South Korea12 sites
The Catholic University of Korea Bucheon St. Mary's Hospital
Bucheon-si, Gyeonggi-do
Daejeon Sun hospital
Daejeon, Daejeon
Wonkwang University Hospital
Iksan, Jeollabuk-do
Inha University Hospital
Incheon, Incheon
Ewha Womans University Mokdong Hospital
Seoul, Seoul
Inje University Seoul Paik Hospital
Seoul, Seoul
Samsung Medical Center
Seoul, Seoul
Seoul Metropolitan Government Seoul National University Boramae Medical Center
Seoul, Seoul
Seoul National University Hospital
Seoul, Seoul
The Catholic University of Korea Seoul St. Mary's Hospital
Seoul, Seoul
The Catholic University of Korea St. Paul's Hospital
Seoul, Seoul
The Catholic University of Korea Vincent's Hospital
Suwon, Gyeonggi-do
About this study
Official title: Random Clinical Trial for Comparison of Efficacy and Safety of Simple Microfracture and Modified Microfracture Using Collagen in the Patients With Knee Cartilage Defects
This study was designed to evaluate the efficacy and safety of a modified microfracture using collagen, and to compare them with those of a simple microfracture to prove the non-inferiority of the modified microfracture using collagen in patients with cartilage defects in their knees.
Read the detailed description
This study was an open-trial study. One hundred subjects participated in it. The study was explained to the subjects and they voluntarily agreed to participate in it. Their eligibility to participate in the study was checked, and they were randomized either into the simple microfracture group or the modified microfracture group using collagen based on a centrally controlled randomization table. They were asked to follow the guidelines of the investigators during the study and to visit the hospital six times*, including for screening. At each visit, the subjects underwent an examination with doctors, a blood test, an X-ray procedure, an MRI, an observation with the naked eyes, and arthroscopy to evaluate the safety and efficacy of the procedure. (*If the screening date overlaps with the procedure date, the number of his or her visits would be five.)
- Being tested
- Microfracture, CartiFill
- Keywords
- Cartilage defect of knee, microfracture, modified microfracture, collagen
- Medical subject headings
- Osteoarthritis, Fractures, Stress
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MicrofractureProcedure or surgery
simple microfracture
CartiFillDevice
add collagen when doing microfracture
| Study group | Role | What they receive |
|---|---|---|
| microfracture | Active comparator | simple microfracture for cartilage defect of knee Receives: Procedure: Microfracture |
| modified microfracture using collagen | Experimental | modified microfracture using collagen (CartiFill) for cartilage defect of knee Receives: Procedure: Microfracture; Device: CartiFill |
What is being measured
The primary outcome is the main question the study is designed to answer.
100mmVAS(Visual Analogue Scale)
It will be evaluated by the VAS score 12 months after surgery of the affected knee of the investigational group and the control group.
Measured: 12 month after surgery
Secondary outcomes (4)
change of 100 mmVAS (Visual Analogue Scale)
The difference between the VAS scores of the affected knee at the screening and 12 months after surgery in the investigational group will be compared to that in the control group. The differences in the VAS scores obtained at the follow-ups (3, 6, and 24 months after surgery) will be compared.
Measured: screening, 3, 6, 12 and 24 months after surgery
change of Knee injury and osteoarthritis outcome (KOOS)
The difference between the KOOS scores of the affected knee at the screening and 12 months after surgery in the investigational group will be compared to that in the control group. The differences in the KOOS scores obtained at the follow-ups (6 and 24 months after surgery) will be compared.
Measured: screening, 6, 12 and 24 months after surgery
change of International Knee Documentation Committee (IKDC)
The difference between the IKDC scores of the affected knee at the screening and 12 months after the surgery in the investigation group will be compared to that in the control group. The differences in the IKDC scores obtained at the follow-ups (6 and 24 months after surgery) will be compared.
Measured: screening, 6, 12 and 24 months after surgery
the results of MRI and MRI of articular cartilage examination (T2, T2 star, deGEMRIC, UTE, etc.), mMOCART
The results obtained 12 months after the surgery on the affected knee in the investigational and control groups will be described. mMOCART will be obtained, and the difference will be assessed.
- Depending on the MRI equipment, if in-house imaging is not possible, it may be done at the other hospitals conducting the research.
Measured: 12 months after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Sep 2015 (estimated)
- Study startFeb 2013
- Primary completionJan 2016 (estimated)
- Study completionJun 2017 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Defect of Articular CartilageStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 100 participants (actual)
Sponsor and investigators
- Lead sponsor
- Cellontech Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Nam Yong Choi, MD, Principal investigator, Catholic University of Korea Saint Paul's HospitalYong In, MD, Principal investigator, The Catholic University of KoreaChan Woong Moon, MD, Principal investigator, The Catholic University of Korea Bucheon St.Mary's HospitalHae Seock Ko, MD, Principal investigator, The Catholic University of Korea Vincent's HospitalCheol Hong Jeon, MD, Principal investigator, Wonkwang University HospitalSeung Back Kang, MD, Principal investigator, SMG-SNU Boramae Medical CenterJa Young Choi, MD, Principal investigator, Seoul National University HospitalMyung Koo Kim, MD, Principal investigator, Inha University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02539030
- Sponsor's protocol ID
- 03CAR
- Status last verified
- Aug 2015
- First submitted
- 28 Aug 2015
- Last updated
- 2 Sep 2015
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Kim MS, Chun CH, Wang JH, Kang SB, Chang MJ, In Y. Microfracture Versus a Porcine-Derived Collagen-Augmented Chondrogenesis Technique for Treating Knee Cartilage Defects: Results at Midterm Follow-up. Orthop J Sports Med. 2024 Nov 7;12(11):23259671241292093. doi: 10.1177/23259671241292093. eCollection 2024 Nov.
PubMed 39525351
Study at a glance
From the registry record, last updated by the sponsor on 2 Sep 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Random Clinical Trial for Comparison of Efficacy and Safety of Simple Microfracture and Modified Microfracture Using Collagen in the Patients With Knee Cartilage Defects
- ClinicalTrials.gov ID
- NCT02539030
- Acronym / sponsor ID
- 03CAR
- Keywords
- Cartilage defect of knee, microfracture, modified microfracture, collagen
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 100 participants (actual)
- Lead sponsor
- Cellontech Co., Ltd.Industry (pharma, biotech, devices)
- Study start
- Feb 2013
- Primary completion
- Jan 2016 (estimated)
- Study completion
- Jun 2017 (estimated)
- First posted
- 2 Sep 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study was designed to evaluate the efficacy and safety of a modified microfracture using collagen, and to compare them with those of a simple microfracture to prove the non-inferiority of the modified microfracture using collagen in patients with cartilage defects in their knees.
Detailed description
This study was an open-trial study. One hundred subjects participated in it. The study was explained to the subjects and they voluntarily agreed to participate in it. Their eligibility to participate in the study was checked, and they were randomized either into the simple microfracture group or the modified microfracture group using collagen based on a centrally controlled randomization table. They were asked to follow the guidelines of the investigators during the study and to visit the hospital six times*, including for screening. At each visit, the subjects underwent an examination with doctors, a blood test, an X-ray procedure, an MRI, an observation with the naked eyes, and arthroscopy to evaluate the safety and efficacy of the procedure. (*If the screening date overlaps with the procedure date, the number of his or her visits would be five.)
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| microfracture | Active comparator | Procedure: Microfracturesimple microfracture for cartilage defect of knee |
| modified microfracture using collagen | Experimental | Procedure: Microfracture, Device: CartiFillmodified microfracture using collagen (CartiFill) for cartilage defect of knee |
Who may qualify
- Ages
- 15 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (2 listed)
- 1. Patients with cartilage defects in their knee (Including Knee OA and Knee TA) 2. Knee osteoarthritis patients whose Kellgren-Lawrence Grading Scale score is lower than 3 (patients who received simultaneous or previous correction will be excluded).
- 3. Patients with misalignment of their tibia and femur, unstable ligament in their knee, or bony defects in the lesions of their knee, and/or who had been treated for alignment 4. Patients who were 15 years old or older 5. Patients or their representative (for adults), or patients and their parent/guardian (for minors), who agreed to participate in the study and signed the informed consent form
Key exclusion criteria (7 listed)
- 1. If patients or their families suffer from or have ever suffered from an autoimmune disease.
- 2. Patients who have ever suffered an anaphylactic reaction. 3. Patients who have ever suffered hypersensitivity to an implant. 4. Patients with a history of allergy to porcine or bovine protein. 5. Subjects with inflammatory arthritis, such as rheumatoid and gouty arthritis.
- 6. Subjects with autoimmune disease related arthritis. 7. Subjects who are pregnant and/or breast-feeding and/or plan a pregnancy. 8. Subjects with tumors. 9. Subjects who have undergone radiotherapy or chemotherapy within the last 2 years (Exception: if the possibility of collagen treatment is confirmed with doctor's clinical decision).
- 10. Subjects who are diabetic. (Exception: if the possibility of CartiFill™ treatment is confirmed with doctor's clinical decision, and/or patient's blood glucose level remains within the normal range and/or no other complications by diabetes mellitus.) 11. Subjects with infections, currently on treatment with antibiotics or antimicrobials (Exception: if the possibility of collagen treatment is confirmed with doctor's clinical decision).
- 12. Subjects under adrenocorticoid therapy (Exception: if the possibility of collagen treatment is confirmed with doctor's clinical decision).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Microfracturesimple microfracture | Procedure or surgery | microfracture, modified microfracture using collagen |
| CartiFilladd collagen when doing microfracture | Device | modified microfracture using collagen |
Primary outcome
100mmVAS(Visual Analogue Scale)
Time frame: 12 month after surgery
It will be evaluated by the VAS score 12 months after surgery of the affected knee of the investigational group and the control group.
4 secondary outcomes
change of 100 mmVAS (Visual Analogue Scale)
Time frame: screening, 3, 6, 12 and 24 months after surgery
change of Knee injury and osteoarthritis outcome (KOOS)
Time frame: screening, 6, 12 and 24 months after surgery
change of International Knee Documentation Committee (IKDC)
Time frame: screening, 6, 12 and 24 months after surgery
the results of MRI and MRI of articular cartilage examination (T2, T2 star, deGEMRIC, UTE, etc.), mMOCART
Time frame: 12 months after surgery
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Sep 2015.
- Derived from this study: PubMed 39525351Kim MS, Chun CH, Wang JH, Kang SB, Chang MJ, In Y. Microfracture Versus a Porcine-Derived Collagen-Augmented Chondrogenesis Technique for Treating Knee Cartilage Defects: Results at Midterm Follow-up. Orthop J Sports Med. 2024 Nov 7;12(11):23259671241292093. doi: 10.1177/23259671241292093. eCollection 2024 Nov.
Related trials for Defect of Articular Cartilage
Recruiting
BioPoly® Partial Resurfacing Knee Implant IDE
Knee Pain Chronic, Knee Osteoarthritis
RecruitingPhase 3
A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle
Chondral Defect, Articular Cartilage Defect
RecruitingPhase 3
A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee
Chondral Defect, Osteochondritis Dissecans (OCD)
Not yet recruiting
Biologic Augmentation of Osteochondral Allograft Transplantation in the Knee
Osteochondral Defect, Articular Cartilage Defect
RecruitingPhase 1
AMIC Compared With Microfracture for Focal Articular Cartilage Damage of the Hip
Hip Arthroscopy, Articular Cartilage Defect
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Nam Yong Choi, MD principal investigator
Catholic University of Korea Saint Paul's Hospital
Yong In, MD principal investigator
The Catholic University of Korea
Chan Woong Moon, MD principal investigator
The Catholic University of Korea Bucheon St.Mary's Hospital
12 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Microfracture and CartiFill in people with Defect of Articular Cartilage and Osteoarthritis, run by Cellontech Co., Ltd. at 12 sites in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 2 Sep 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 12 sites in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
100mmVAS(Visual Analogue Scale) (time frame: 12 month after surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02539030, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Sep 2015.